Can we effective use sym004 in tumours harboring EGFR extracellular domain mutations?

Colorectal cancer (CRC) is the third most common cancer worldwide and the fourth most common cause of death (1). The therapeutic options available for the treatment of metastatic CRC have significantly increased over the past years. Together with the advances in surgical techniques, the introduction of irinotecan and oxaliplatin first and drugs targeting vascular endothelial growth factor (VEGF) or epidermal growth factor receptor (EGFR) later, have led to a median overall survival (OS) now approaching 30 months (2)